Is SNY or SPRY more undervalued in 2026?

CirclFi compares Sanofi (SNY) and ARS Pharmaceuticals, Inc. (SPRY) using 13 institutional-grade valuation models. SNY has a Quality of Company score of 7.3/10 while SPRY scores 4.7/10.

Which is a better buy — SNY or SPRY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SNY and SPRY valuations compare?

SNY at $43.67 and SPRY at $9.07 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SNY vs SPRY Valuation Comparison 2026 — Intrinsic Value Analysis

SNY

Pharmaceutical Preparations

Sanofi

Quality

7.3

out of 10

Value Trap

SAFE

Price

$43.67

Last close

Models

13/13

Active

SPRY

Pharmaceutical Preparations

ARS Pharmaceuticals, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$9.07

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	SNY Fair Value	SNY Upside	SPRY Fair Value	SPRY Upside
Bayesian DCF	Intrinsic	$81.10	+85.7%	$1.86	-79.5%
Earnings Power Value	Intrinsic	$30.11	-31.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$115.05	+163.5%	$1.53	-83.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SNY vs SPRY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SNY vs SPRY — Which Stock Is More Undervalued?

SNY scores higher with a 7.3/10 quality rating vs SPRY's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sanofi (SNY) and ARS Pharmaceuticals, Inc. (SPRY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SNY currently trades at $43.67 with a QOC of 7.3/10, while SPRY trades at $9.07 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).